The reference method for FeNO testing from newborn to adult patients

The ANALYZER CLD 88 sp FeNO analyzer is the reference for continuous, simultaneous measurement and display of NO values, flow rate and volume of the exhaled breath. This sensitive instrument guarantees reproducible and reliable results. It is approved in accordance to CE MDD for clinical use and fully compliant to the 2005 ATS/ERS recommendations for FeNO analysis. One instrument for all applications, from infants (>3 kg) to adults.

High sensitivity and reproducibility

The ANALYZER CLD 88 sp offers high sensitivity and speed as demanded in clinical and research applications. NO concentrations down to 0.1 ppb can be detected.

Numerous application options in one system

The ANALYZER CLD 88 sp can be used for FeNO testing on infants (>3 kg), children and adults. Single breath tests for cooperative patients as well as multiple breath tests for non-cooperative patients are possible. The instrument can also measure nasal and alveolar NO. Tests can be carried out online or offline.

Options for extended application range

Several options are available for the ANALYZER CLD 88 sp. The DENOX 88 module supplies NO free air and controls the expiratory flow during the single breath test. An offline NO collection kit is available for tests remote from the instrument.

Easy to use

Performing an NO measurement is very simple with the ANALYZER CLD 88 sp. The instrument is controlled by the SPIROWARE® software, which let’s the user start, record and evaluate a measurement with a few mouse clicks only. All key parameters and graphs are displayed in the results section and the screen can be customized for individual preferences.

NO-measurement Measuring ranges: 0.1-5000 ppb
Min. detectable concentration: 0.06 ppb *
Zero drift: <0.5 ppb per 6 h
Linearity: ± 1% full scale
Lag time: < 0.5 s, software compensated
Rise time (T90): < 100 ms
Sample flow: selectable type 1 or 3 (110 or 330 ml/min)
Flow measurement Measuring range:
±0.5 l/s (DSR small: VD 1.9 ml, optional)
±1.5 l/s (DSR medium: VD 7.2 ml)
±16 l/s (Spirette)
Min. detectable flow: 0.6 ml
Accuracy: ±2%
General Temperature range: 10-40 °C
Humidity tolerance: 5-95% rel. humidity (non-condensing)
Ozone Generator: internal, maintenance free (no external supply gas required)
Power consumption: 400 VA
Supply voltage: 100-240 V / 50-60 Hz
Interface: RS-232 (Standard)
Weight: 24 kg
Dimensions: HxWxD: 135 x 500 x 540 mm (5¼ x 19 x 17 “)
System requirements Intel Core i5 type processor or higher, compliant to the Council Directive 93/42 EEC concerning medical devic-es and the European Safety Standard EN 60601-1 (e.g. ViewMedic Clinico 222C3, Rein Medical GmbH, 47877 Willich, Germany), Microsoft Windows WIN 7 or higher and .NET Framework 4.0 and MS Visual C++ 2010
16 MB of RAM, 10GB of free disk space, XGA or better graphics and USB 2.0 port

(*) Depending on sample flow

System includes: ANALYZER CLD 88 sp, integrated ultrasonic Spirometer, sample tube type 3, mains- and RS-232-cable, operator’s Manual, SPIROWARE® 3.x software
(Note: Computer, printer, NO-calibration gases and NO free air supply are not part of delivery)

ECO MEDICS reserves the right to change these specifications without notice.


  • Single breath tests for cooperative patients
  • Multiple breath tests for non-cooperative patients
  • Nasal nitric oxide measurements
  • Offline NO collection kit
  • Alveolar FeNO analysis

Your Advantage

  • Noninvasive detection of lung inflammation (e.g. asthma)
  • Verification of anti-inflammatory treatment
  • Detection of non-responders
  • Various flow ranges for research applications (JNO, Calv calculations)
  • PCD screening
  • CE MDD 93/42 approved for clinical use
  • Compliance with the “ATS/ERS Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide, 2005”

ATS / ERS reference

The ANALYZER CLD 88 sp with SPIROWARE® 3.x is CE MDD (0483) approved for clinical use. The chemiluminescence detection method is the only ATS / ERS recommended measurement principle for exhaled Nitric Oxide analysis (FeNO test – Gold Standard) to fulfill the requirements for detection limit, response time and measurement range.



  1. ATS/ERS Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide, 2005; ATS Board of Directors, December 2004, and by the ERS Executive Committee, June 2004
  2. A. T. Society, E. R. Society, ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 171, 912-930 (2005).
  3. E. Baraldi, J. C. de Jongste, E. R. S. A. T. S. E. A. T. Force, Measurement of exhaled nitric oxide in children, 2001. Eur Respir J 20, 223-237 (2002).
  4. Recommendations for standardized procedures for the on-line and off-line measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 160, 2104-2117 (1999).
  5. M. Olivieri et al., Reference values for exhaled nitric oxide (reveno) study. Respir Res 7, 94 (2006).
  6. D. A. Straub, S. Minocchieri, A. Moeller, J. Hamacher, J. H. Wildhaber, The effect of montelukast on exhaled nitric oxide and lung function in asthmatic children 2 to 5 years old. Chest 127, 509-514 (2005).
  7. E. Baraldi, M. F. Pasquale, A. M. Cangiotti, S. Zanconato, F. Zacchello, Nasal nitric oxide is low early in life: case study of two infants with primary ciliary dyskinesia. Eur Respir J 24, 881-883 (2004).
  8. X. Baur, L. Barbinova, Latex allergen exposure increases exhaled nitric oxide in symptomatic healthcare workers. Eur Respir J 25, 309-316 (2005).
  9. G. M. Verleden et al., Exhaled nitric oxide after lung transplantation: impact of the native lung. Eur Respir J 21, 429-432 (2003).
  10. D. C. Törnberg et al., Nasal and oral contribution to inhaled and exhaled nitric oxide: a study in tracheotomized patients. Eur Respir J 19, 859-864 (2002).
  11. G. L. Hall, B. Reinmann, J. H. Wildhaber, U. Frey, Tidal exhaled nitric oxide in healthy, unsedated newborn infants with prenatal tobacco exposure. J Appl Physiol (1985) 92, 59-66 (2002).
  12. M. Högman, P. Meriläinen, Extended NO analysis in asthma. J Breath Res 1, 024001 (2007).
  13. N. M. Tsoukias, S. C. George, A two-compartment model of pulmonary nitric oxide exchange dynamics. J Appl Physiol (1985) 85, 653-666 (1998).

FeNO Testing

Exhaled nitric oxide analysis for asthma management and PCD screening in cooperative and non-cooperative patients

ANALYZER CLD 88 sp – FeNO analysis by single and multiple breath testing; bronchial, alveolar and nasal FeNO

Pulmonary Function Testing

Detection and monitoring of ventilation inhomogeneity and small airway diseases such as asthma, cystic fibrosis and COPD

EXHALYZER D – Nitrogen washout by single breath or multiple breath (SBW or MBW), breathing pattern (TBFVL), FRC, LCI, moment ratios and slope analysis

Infant Pulmonary Function Testing

Suitable for cooperative and non-cooperative patients from infants >3kg body weight to adults

EXHALYZER D – Breathing pattern (TBFVL), FRC, LCI and SOT analysis for patients > 3 kg body weight

Liquid NO analysis

Nitric oxide analyzer for liquid samples from biomedical or pharmaceutical applications

ANALYZER CLD 88 – Liquid NO detection in combination with liquid purge vessel and chromatographic software